4-cyclohexyl-N-methylbenzamide | 923692-05-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-cyclohexyl-N-methylbenzamide
• CAS: 923692-05-1
• 化学式: C₁₄H₁₉NO
• mdl: MFCD08851715
• 分子量: 217.311
• InChiKey: ZVACURLLRBTWGN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  乙烯基环己烷 在 bis(1,5-cyclooctadiene)nickel (0) 、 三乙胺 、 4,4'-二叔丁基-2,2'-二吡啶 作用下， 以 1,2-二氯乙烷 、 丙酮 为溶剂， 反应 36.0h， 生成 4-cyclohexyl-N-methylbenzamide
  参考文献：
  名称：

  由四嗪和光激发实现的脱烯基镍催化交叉偶联

  摘要：

  已经开发出一种新的通用方法来官能化烷基和烯烃键的 C(sp 3 )–C(sp 2 ) 键，导致碳中心自由基的脱烯基生成，这些自由基可以被截获以进行 Ni 催化的 C( sp 3 )–C(sp 2 ) 交叉耦合。这种一锅法利用易于获得的烯烃原料进行有机合成，具有出色的官能团兼容性，无需光氧化还原催化剂。

  DOI：

  10.1021/jacs.1c05092

文献信息

• Ruthenium-Catalyzed Para-Selective Oxidative Cross-Coupling of Arenes and Cycloalkanes
  作者：Xiangyu Guo、Chao-Jun Li

  DOI：10.1021/ol202081c

  日期：2011.10.7

  A novel, direct para-selective oxidative cross-coupling of benzene derivatives with cycloalkanes catalyzed by ruthenium was developed. A wide range of arenes bearing electron-withdrawing substituents was functionalized directly with simple cycloalkanes with high para-selectivity; arenes with electron-donating groups were mainly para-functionalized. Benzoic acid can be used directly.

  开发了一种新型的，钌催化的苯衍生物与环烷烃直接对位选择性氧化交联的方法。带有吸电子取代基的多种芳烃直接用具有高对位选择性的简单环烷烃直接官能化；具有给电子基团的芳烃主要是超官能化的。苯甲酸可直接使用。
• Micelle enabled C(sp²)–C(sp³) cross-electrophile coupling in water <i>via</i> synergistic nickel and copper catalysis
  作者：Ning Ye、Bin Wu、Kangming Zhao、Xiaobin Ge、Yu Zheng、Xiaodong Shen、Lei Shi、Margery Cortes-Clerget、Morgan Louis Regnier、Michael Parmentier、Fabrice Gallou

  DOI：10.1039/d1cc02885e

  日期：——

  A robust and sustainable C(sp²)–C(sp³) cross-electrophile coupling was developed via nickel/copper synergistic catalysis under micellar conditions.

  通过镍/铜协同催化在胶束条件下开发了稳健且可持续的C(sp²)–C(sp³)交叉电愿偶联。
• 5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor
  申请人：Mizojiri Ryo

  公开号：US20090036444A1

  公开（公告）日：2009-02-05

  The present invention relates to a fused ring compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及一种由以下式[I]表示的融合环化合物，其中每个符号如规范中所定义，或其药学上可接受的盐，以及一种丙型肝炎病毒（HCV）聚合酶抑制剂和治疗丙型肝炎的药物，本发明的化合物基于HCV聚合酶抑制活性具有抗HCV活性，是一种预防或治疗丙型肝炎的药剂。
• Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
  申请人：Oka Takahiro

  公开号：US20070049593A1

  公开（公告）日：2007-03-01

  The present invention relates to a tetracyclic fused heterocyclic compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及一种四环融合杂环化合物，其化学式为[I]，其中每个符号的定义如规范中所述，或其药学上可接受的盐，以及一种丙型肝炎病毒（HCV）聚合酶抑制剂和治疗丙型肝炎的药物，本发明的化合物表现出基于HCV聚合酶抑制活性的抗HCV活性，因此可用作预防或治疗丙型肝炎的药物。
• TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR
  申请人：Oka Takahiro

  公开号：US20120070409A1

  公开（公告）日：2012-03-22

  The present invention relates to a tetracyclic fused heterocyclic compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及一种四环融合杂环化合物，其表示为以下公式[I]，其中每个符号如规范中所定义，或其药学上可接受的盐，以及一种丙型肝炎病毒（HCV）聚合酶抑制剂和治疗丙型肝炎的药物，本发明的化合物基于HCV聚合酶抑制活性显示出抗HCV活性，可用作预防或治疗丙型肝炎的药物。